Jump to content

BREAKING NEWS! Tarceva SATURN phase global III study info


Recommended Posts




First EGFR Targeted and Oral Therapy to Improve Progression-Free Survival in

Patients with Advanced Non-Small Cell Lung Cancer Following Initial Treatment --

South San Francisco, Calif., and Melville, New York — November 6, 2008 —

Genentech, Inc., (NYSE: DNA) and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today

announced that a global Phase III study (SATURN) met its primary endpoint and

showed Tarceva® (erlotinib) significantly extended the time patients with advanced nonsmall cell lung cancer (NSCLC) lived without their cancer getting worse when given

immediately following initial treatment with platinum-based chemotherapy, compared to

placebo. There were no new or unexpected safety signals in the study and adverse

events were consistent with those observed in previous NSCLC clinical trials evaluating


The SATURN study results are being fully analyzed and the data will be

submitted for presentation at a future medical meeting. OSI, Genentech and Roche will

discuss next steps for a potential new indication for Tarceva with the U.S. Food and

Drug Administration (FDA) and European Health Authorities.

“We believe that Tarceva as a once-a-day oral therapy, which has a wellestablished

safety profile, may be well-suited as a maintenance therapy in the first-line

setting following chemotherapy,” said Gabriel Leung, President, OSI Oncology. “We are

excited about the prospect that for the first time patients may have a treatment

alternative that is different from traditional chemotherapy and extends the time patients

live without their cancer progressing following initial treatment.”

“We are pleased by the findings as they represent another step forward in our

hopes of providing more options to patients throughout their battle with lung cancer,”

said Hal Barron, M.D., Genentech’s senior vice president, Development and chief

medical officer.

Tarceva is currently approved as a second-line treatment for patients with

advanced NSCLC, who have progressed following treatment with at least one prior

chemotherapy regimen, based on a 37 percent improvement in overall survival

compared to placebo (hazard ratio 0.73).

“There is an unmet need for treatments that can be used as early as possible

following initial treatment of NSCLC and the results from the SATURN study provide a

strong rationale for introducing Tarceva as a maintenance therapy in this difficult to treat

disease," said Professor F. Capuzzo, M.D., Istituto Clinico Humanitas IRCCS, Milan,

Italy and lead investigator of the SATURN study.

According to the American Cancer Society (ACS) lung cancer is the single

largest cause of cancer deaths among men and women in the United States and is

responsible for nearly 30 percent of cancer deaths. The ACS estimates that in 2008

more than 215,000 Americans will be diagnosed with lung cancer and 162,000 will die

of the disease. NSCLC is the most common type of lung cancer.


SATURN is a placebo-controlled, randomized, double-blind, Phase III study conducted

by Roche that enrolled 889 patients with advanced NSCLC at approximately 160 sites

worldwide. Patients were treated with at least four cycles of standard first-line platinumbased chemotherapy and were then randomized to Tarceva or placebo if their cancer did not progress. The primary endpoint of the study was progression-free survival.

Secondary endpoints included overall survival, safety and an evaluation of exploratory


About Tarceva

Tarceva is a small molecule designed to target the EGFR pathway, which is one of the

factors critical to cell growth in NSCLC and pancreatic cancers. Tarceva is designed to

inhibit the tyrosine kinase activity of the EGFR signaling pathway inside the cell.

Tarceva is FDA-approved for use as a monotherapy in patients with locally

advanced or metastatic NSCLC whose disease has progressed after one or more

courses of chemotherapy. Results from two, multicenter, placebo-controlled,

randomized, Phase III trials conducted in first-line patients with locally advanced or

metastatic NSCLC showed no clinical benefit with the concurrent administration of

Tarceva with platinum-based chemotherapy (carboplatin and paclitaxel or gemcitabine

and cisplatin) and its use is not recommended in that setting.

Tarceva is also approved in combination with gemcitabine for the treatment of

patients who have not received previous chemotherapy for locally advanced pancreatic

cancer, pancreatic cancer that cannot be surgically removed or pancreatic cancer that

has spread to distant body organs.

Tarceva Safety

There have been infrequent reports of serious Interstitial Lung Disease (ILD)-like events,

including fatalities, in patients receiving Tarceva for treatment of NSCLC, pancreatic

cancer or other advanced solid tumors. Cases of hepatic failure, hepatorenal syndrome,

acute renal failure (all including fatalities), and renal insufficiency have been reported

during use of Tarceva. When receiving Tarceva therapy, women should be advised

against becoming pregnant or breastfeeding. Tarceva is pregnancy category D. The

most common adverse reactions in patients with NSCLC receiving Tarceva

monotherapy were rash and diarrhea. The most common adverse reactions in patients

with pancreatic cancer receiving Tarceva plus gemcitabine were fatigue, rash, nausea,

anorexia, and diarrhea.

For full prescribing information, please call 1-877-TARCEVA or visit


About Genentech

Founded more than 30 years ago, Genentech is a leading biotechnology company that

discovers, develops, manufactures and commercializes medicines for patients with

significant unmet medical needs. The company has headquarters in South San

Francisco, California and is listed on the New York Stock Exchange under the symbol

DNA. For additional information about the company, please visit http://www.gene.com.

About OSI Pharmaceuticals

OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by

discovering, developing and commercializing high-quality and novel pharmaceutical

products designed to extend life and/or improve the quality of life for patients with

cancer and diabetes/obesity.

The Company's oncology programs are focused on developing molecular targeted

therapies designed to change the paradigm of cancer care. OSI's diabetes/obesity

efforts are committed to the generation of novel, targeted therapies for the treatment of type 2 diabetes and obesity. OSI's flagship product, Tarceva® (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitorto have demonstrated the ability to improve survival in both NSCLC and pancreatic cancer patients in certain settings. OSI markets Tarceva through partnerships with Genentech, Inc. in the United States and with Roche throughout the rest of the world.

For additional information about OSI, please visit (http://www.osip.com).


Genentech Safe Harbor Statement

This press release contains forward-looking statements regarding the potential for Tarceva and approval

for Tarceva in the first-line maintenance setting for NSCLC. Such statements are predictions and involve

risks and uncertainties such that actual results may differ materially. Actual results may be affected by a

number of factors including, but not limited to, unexpected safety, efficacy or manufacturing issues, the

need for additional data, data analysis or clinical studies, NDA preparation, FDA actions or delays, failure

to obtain or maintain FDA approval, competition, pricing, reimbursement, the ability to supply product,

product withdrawals and new product approvals and launches, and intellectual property or contract rights.

Please also refer to the risk factors described in Genentech's periodic reports filed with the Securities and

Exchange Commission. Genentech disclaims, and does not undertake, any obligation to update or revise

any forward-looking statement in this press release.

OSI Safe Harbor Statement

This news release contains forward-looking statements. These statements are subject to known and

unknown risks and uncertainties that may cause actual future experience and results to differ materially

from the statements made. Factors that might cause such a difference include, among others, the results

from, and the ability to complete, clinical trials, the FDA review process and other governmental

regulation, OSI's and its collaborators' abilities to successfully develop and commercialize drug

candidates, competition from other pharmaceutical companies, the ability to effectively market products,

and other factors described in OSI Pharmaceuticals' filings with the Securities and Exchange Commission.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.